Literature DB >> 11839723

Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 mismatch repair genes: implications for genetic testing.

M Cravo1, A J Afonso, P Lage, C Albuquerque, L Maia, C Lacerda, P Fidalgo, P Chaves, C Cruz, C Nobre-Leitão.   

Abstract

BACKGROUND: In hereditary non-polyposis colorectal cancer, over 90% of the identified mutations are in two genes, hMSH2 and hMLH1. A large proportion of the mutations detected in these genes are of the missense type which may be either deleterious mutations or harmless polymorphisms. AIM: To investigate whether nine missense and one splice site mutation of hMLH1 and hMSH2, in 10 kindreds with a familial history of colorectal cancer or young age of onset, could be interpreted as pathogenic.
METHODS: Clinical and genetic characteristics were collected: (i) evolutionary conservation of the codon involved; (ii) type of amino acid change; (iii) occurrence of mutation in healthy controls; (iv) cosegregation of mutation with disease phenotype; (v) functional consequences of gene variant; and (vi) microssatellite instability and immunoexpression of hMSH2 and hMLH1 analysis.
RESULTS: Seven different missense and one splice site mutation were identified. Only 1/8 was found in the control group, 2/7 occurred in conserved residues, and 5/7 resulted in non-conservative changes. Functional studies were available for only 2/8 mutations. Segregation of the missense variant with disease phenotype was observed in three kindreds.
CONCLUSION: In the majority of families included, there was no definitive evidence that the missense or splice site alterations were causally associated with an increased risk of developing colorectal cancer. Until further evidence is available, these mutational events should be regarded and interpreted carefully and genetic diagnosis should not be offered to these kindreds.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11839723      PMCID: PMC1773142          DOI: 10.1136/gut.50.3.405

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  38 in total

1.  Missense and nonsense mutations in codon 659 of MLH1 cause aberrant splicing of messenger RNA in HNPCC kindreds.

Authors:  M Nyström-Lahti; M Holmberg; P Fidalgo; R Salovaara; A de la Chapelle; J Jiricny; P Peltomäki
Journal:  Genes Chromosomes Cancer       Date:  1999-12       Impact factor: 5.006

2.  The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer.

Authors:  S Guerrette; S Acharya; R Fishel
Journal:  J Biol Chem       Date:  1999-03-05       Impact factor: 5.157

3.  Missense mutations in hMLH1 associated with colorectal cancer.

Authors:  T Liu; P Tannergård; P Hackman; C Rubio; U Kressner; G Lindmark; D Hellgren; B Lambert; A Lindblom
Journal:  Hum Genet       Date:  1999-11       Impact factor: 4.132

4.  MSH2 sequence variations and inherited colorectal cancer susceptibility.

Authors:  N J Froggatt; J A Joyce; D G Evans; P W Lunt; D J Koch; B J Ponder; E R Maher
Journal:  Eur J Cancer       Date:  1996-01       Impact factor: 9.162

5.  Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.

Authors: 
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

6.  Assessment of pathogenicity criteria for constitutional missense mutations of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2.

Authors:  M Genuardi; S Carrara; M Anti; M Ponz de Leòn; A Viel
Journal:  Eur J Hum Genet       Date:  1999 Oct-Nov       Impact factor: 4.246

7.  Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing.

Authors:  S Syngal; E A Fox; C Li; M Dovidio; C Eng; R D Kolodner; J E Garber
Journal:  JAMA       Date:  1999-07-21       Impact factor: 56.272

Review 8.  Genetic testing in hereditary colorectal cancer: indications and procedures.

Authors:  J P Terdiman; P G Conrad; M H Sleisenger
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

9.  Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and controls.

Authors:  S M Farrington; J Lin-Goerke; J Ling; Y Wang; J D Burczak; D J Robbins; M G Dunlop
Journal:  Am J Hum Genet       Date:  1998-09       Impact factor: 11.025

10.  Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations.

Authors:  S Syngal; J C Weeks; D Schrag; J E Garber; K M Kuntz
Journal:  Ann Intern Med       Date:  1998-11-15       Impact factor: 25.391

View more
  16 in total

1.  Functional interrogation of Lynch syndrome-associated MSH2 missense variants via CRISPR-Cas9 gene editing in human embryonic stem cells.

Authors:  Abhijit Rath; Akriti Mishra; Victoria Duque Ferreira; Chaoran Hu; Gregory Omerza; Kevin Kelly; Andrew Hesse; Honey V Reddi; James P Grady; Christopher D Heinen
Journal:  Hum Mutat       Date:  2019-08-17       Impact factor: 4.878

2.  An MLH1 mutation links BACH1/FANCJ to colon cancer, signaling, and insight toward directed therapy.

Authors:  Jenny Xie; Shawna Guillemette; Min Peng; Candace Gilbert; Andrew Buermeyer; Sharon B Cantor
Journal:  Cancer Prev Res (Phila)       Date:  2010-10-26

3.  A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay.

Authors:  Francesca Bianchi; Elena Maccaroni; Laura Belvederesi; Cristiana Brugiati; Riccardo Giampieri; Federica Bini; Raffaella Bracci; Silvia Pagliaretta; Michela Del Prete; Francesco Piva; Alessandra Mandolesi; Marina Scarpelli; Rossana Berardi
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

4.  Germline mutations of the hMLH1 and hMSH2 mismatch repair genes in Belgian hereditary nonpolyposis colon cancer (HNPCC) patients.

Authors:  M Spaepen; B Vankeirsbilck; S Van Opstal; S Tejpar; E Van Cutsem; K Geboes; E Legius; G Matthijs
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

5.  Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment.

Authors:  Laura Belvederesi; Francesca Bianchi; Cristian Loretelli; Raffaella Bracci; Stefano Cascinu; Riccardo Cellerino
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

6.  Evaluation of reported pathogenic variants and their frequencies in a Japanese population based on a whole-genome reference panel of 2049 individuals.

Authors:  Yumi Yamaguchi-Kabata; Jun Yasuda; Osamu Tanabe; Yoichi Suzuki; Hiroshi Kawame; Nobuo Fuse; Masao Nagasaki; Yosuke Kawai; Kaname Kojima; Fumiki Katsuoka; Sakae Saito; Inaho Danjoh; Ikuko N Motoike; Riu Yamashita; Seizo Koshiba; Daisuke Saigusa; Gen Tamiya; Shigeo Kure; Nobuo Yaegashi; Yoshio Kawaguchi; Fuji Nagami; Shinichi Kuriyama; Junichi Sugawara; Naoko Minegishi; Atsushi Hozawa; Soichi Ogishima; Hideyasu Kiyomoto; Takako Takai-Igarashi; Kengo Kinoshita; Masayuki Yamamoto
Journal:  J Hum Genet       Date:  2017-12-01       Impact factor: 3.172

7.  Prediction and assessment of splicing alterations: implications for clinical testing.

Authors:  Amanda B Spurdle; Fergus J Couch; Frans B L Hogervorst; Paolo Radice; Olga M Sinilnikova
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

8.  Genetic variation in genes for the xenobiotic-metabolizing enzymes CYP1A1, EPHX1, GSTM1, GSTT1, and GSTP1 and susceptibility to colorectal cancer in Lynch syndrome.

Authors:  Mala Pande; Christopher I Amos; Daniel R Osterwisch; Jinyun Chen; Patrick M Lynch; Russell Broaddus; Marsha L Frazier
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

9.  Investigation on the role of nsSNPs in HNPCC genes--a bioinformatics approach.

Authors:  C George Priya Doss; Rao Sethumadhavan
Journal:  J Biomed Sci       Date:  2009-04-24       Impact factor: 8.410

10.  Assessing pathogenicity of MLH1 variants by co-expression of human MLH1 and PMS2 genes in yeast.

Authors:  Matjaz Vogelsang; Aleksandra Comino; Neja Zupanec; Petra Hudler; Radovan Komel
Journal:  BMC Cancer       Date:  2009-10-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.